ClinicalTrials.gg
CompletedNCT04542070SOLARUpdated Jun 4, 2024Results posted

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

A Phase 3 interventional study of Cabotegravir Tablets and Cabotegravir Injectable Suspension (CAB LA) in HIV Infections, sponsored by ViiV Healthcare. Completed at 117 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-04.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
687
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.

Enrollment
7th of 36
687 · median 200
Started
2020
with 5 others
Phase 3
12 of 36
2 open now
Registered
22nd of 36
by date
Lead sponsor
24 of 36
ViiV Healthcare

Among the 36 studies testing cabotegravir in HIV Infections, this one is the 7th largest by enrollment, is one of 6 that started in 2020, is one of 12 in phase 3, and was the 22nd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cabotegravir

cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cabotegravir in HIV Infections, or all of them as a file.
02

Study summary

This study is designed to assess the antiviral activity and safety of a two-drug regimen of CAB LA + RPV LA compared with maintenance of BIK. BIKTARVY is a registered trademark of Gilead Sciences.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV
  • Cabotegravir
  • Rilpivirine
  • BIKTARVY
  • Antiretroviral therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged 18 years or older (or >=19 where required by local regulatory agencies), at the time of signing the .
  • A female participant is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotropin (hCG) test at screen and a negative urine hCG test at Randomization), not lactating, and at least one of the following conditions applies.

    1. Non- defined as:

      • Pre-menopausal females with one of the following:

        1. Documented tubal ligation.
        2. Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion.
        3. Hysterectomy.
        4. Documented Bilateral Oophorectomy
      • defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] and estradiol levels consistent with menopause). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment.
    2. Reproductive potential and agrees to follow one of the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from 30 days prior to the first dose of study medication, throughout the study, for at least 30 days after discontinuation of all oral study medications, and for at least 52 weeks after discontinuation of CAB LA and RPV LA.
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the consent form and in this protocol. Eligible participants or their legal guardians (and next of kin when locally required), must sign a written Informed Consent Form before any protocol-specified assessments are conducted. Enrollment of participants who are unable to provide direct informed consent is optional and will be based on local legal/regulatory requirements and site feasibility to conduct protocol procedures.
  • Participants enrolled in France must be affiliated to, or a beneficiary of, a social security category.
  • Must be on the uninterrupted current regimen of BIK for at least 6 months prior to Screening with an undetectable -1 viral load for at least 6 months prior to Screening. BIK must be the participant's first or second regimen. If BIK is the second regimen, the first regimen must be an integrase inhibitor (INI) regimen. Only a single prior Integrase inhibitor (INI) regimen is allowed if BIK is a regimen >=6 months prior to screening. Any history of non-integrase strand transfer inhibitor regimens (that is. non-nucleoside reverse transcriptase inhibitor, protease inhibitor, C-C chemokine receptor 5 and other entry inhibitors) are not permitted. Any prior change in regimen, defined as a change of a single drug or multiple drugs simultaneously, must have occurred due to tolerability/safety, access to medications, or convenience/simplification, and must not have been done for treatment failure (HIV-1 RNA >=400 c/mL).

The following are limited exceptions:

  • A change from Tenofovir disoproxil fumarate (TDF) to TAF will not be considered a regimen change.
  • Historical perinatal use of Nucleoside reverse transcriptase inhibitor (NRTI) when given in addition to an ongoing Highly active antiretroviral therapy (HAART) will not be considered a change in ART therapy regimen.
  • The past use of ARVs in the context of Post Exposure Prophylaxis (PEP) or Pre-Exposure Prophylaxis (PrEP) while the participant was HIV negative will be allowed. Such cases will be evaluated on a case by case basis with the Medical Monitor, and may require documentation of HIV negative serology during time of PEP or PrEP.
  • A change in dosing scheme of the same drug from twice daily to once daily will not be considered a change in ART regimen if data support similar exposures and efficacy.
  • A change in formulation from multiple class regimens to single treatment regimens (of the same medications) would not be considered a change in ART regimen.

    • Documented evidence of plasma HIV-1 RNA measurements \<50 c/mL in the 6 months prior to Screening.
    • Plasma HIV-1 RNA \<50 c/mL at Screening.

Exclusion criteria

Exclusion Criteria:

  • Within 6 months prior to Screening, any plasma -1 RNA measurement >=50 c/mL.
  • Within the 6 to 12-month window prior to Screening, documented evidence of any plasma HIV-1 RNA measurement greater than (>)200 c/mL, or 2 or more plasma HIV-1 RNA measurements >=50 c/mL.
  • History of prior treatment failure to any Department of Health and Human Services (DHHS) recommended ART regimen.
  • History of drug holiday >1 month for any reason prior to Screening visit, except where all ART was stopped due to tolerability and/or safety concerns.
  • Any change to a regimen, defined as change of a single drug or multiple drugs simultaneously, due to virologic failure to therapy (defined as a confirmed plasma HIV 1 RNA measurement >=200 c/mL after initial suppression to \<50 c/mL while on first line HIV therapy regimen).
  • Participants who are currently participating in or anticipate being selected for any other interventional study.
  • Women who are pregnant, breastfeeding or plan to become pregnant or breastfeed during the study.
  • Any evidence of a current Center for Disease Control and Prevention (CDC) Stage 3 disease except cutaneous Kaposi's sarcoma not requiring systemic therapy, and \<200 cells/microliter are not exclusionary.
  • Participants with moderate to severe hepatic impairment.
  • Any pre-existing physical or mental condition (including substance use disorder) which, in the opinion of the Investigator, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
  • Participants determined by the Investigator to have a high risk of seizures, including participants with an unstable or poorly controlled seizure disorder. A participant with a prior history of seizure may be considered for enrollment if the Investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the Medical Monitor prior to enrollment.
  • All participants will be screened for syphilis.

    • Participants with untreated secondary (late latent) or tertiary syphilis infection, defined as a positive rapid plasma reagin (RPR) and a positive treponemal test without clear documentation of treatment, are excluded.
    • Participants with a false positive RPR (with negative treponemal test) or serofast RPR result (persistence of a reactive nontreponemal syphilis test despite history of adequate therapy and no evidence of re-exposure) may enroll after consultation with the Medical Monitor.
    • Participants with primary syphilis or early latent secondary syphilis (acquired within the preceding year) who have a positive RPR test and have not been treated may be treated during the screening period and if completion of antibiotic treatment occurs during the screening period, may be allowed entry after consultation with the Medical Monitor. If antibiotic treatment cannot be completed before the screening window ends, participants may be rescreened once following completion of antibiotic therapy for primary or early latent secondary syphilis.
  • Participants who, in the investigator's judgment, pose a significant suicide risk. Participant's recent history of suicidal behavior and/or suicidal ideation should be considered when evaluating for suicide risk.
  • The participant has a tattoo, gluteal implant/enhancements or other dermatological condition overlying the gluteus region which may interfere with interpretation of injection site reactions.
  • Evidence of virus (HBV) infection based on the results of testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), Hepatitis B surface antibody (anti-HBs) and HBV deoxyribonucleic acid (DNA) as follows:

    1. Participants positive for HBsAg are excluded.
    2. Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg status), whether negative or positive for HBV DNA, are excluded.
  • Asymptomatic individuals with chronic virus (HCV) infection will not be excluded, however Investigators must carefully assess if therapy specific for HCV infection is required; participants who require or qualify for immediate HCV treatment are excluded for those co-infected participants who post entry into Switch Onto Long Acting Regimen (SOLAR) decide treatment for HCV infection is warranted or desired either by the participant or by the treating physician.

Participants with HCV co-infection will be allowed entry into this study if:

  1. Liver enzymes meet entry criteria
  2. HCV Disease has undergone appropriate work-up, and is not advanced, and will not require treatment prior to the Month 14 visit. Additional information (where available) on participants with HCV co-infection at screening should include results from any liver , Fibroscan, ultrasound, or other fibrosis evaluation, history of cirrhosis or other decompensated liver disease, prior treatment, and timing/plan for HCV treatment.
  3. In the event that recent biopsy or imaging data is not available or inconclusive, the fibrosis (Fib)-4 score will be used to verify eligibility

i. Fib-4 score >3.25 is exclusionary ii. Fib-4 scores 1.45-3.25 requires Medical Monitor consultation Fibrosis 4 Score Formula: d. Age x (AST)/ x (square [Alanine aminotransferase {ALT}]).

  • Unstable liver disease (as defined by any of the following: presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice or cirrhosis, or decompensated cirrhosis [for example {e.g.} ascites, encephalopathy, or variceal bleeding]), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment).
  • History of liver cirrhosis with or without hepatitis viral co-infection.
  • Ongoing or pancreatitis
  • Clinically significant cardiovascular disease, as defined by history/evidence of congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease.
  • Ongoing other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the Study medical monitor for inclusion of the participant prior to randomization.
  • Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study medication.
  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class. In addition, if heparin is used during pharmacokinetic (PK) sampling, participants with a history of sensitivity to heparin or heparin-induced thrombocytopenia must not be enrolled.
  • Current or anticipated need for chronic anti-coagulation with the exception of the use of low dose acetylsalicylic acid (less than or equal to [\<=]325 milligram) or hereditary coagulation and platelet disorders such as hemophilia or Von Willebrand Disease.
  • interval (QTc [Bazett]) >450 milliseconds (msec) or QTc (Bazett) >480 msec for participants with bundle branch block.
  • Known or suspected active Coronavirus Disease-2019 (COVID-19) infection or has had contact with an individual with known COVID-19, within 14 days of study enrollment.
  • Known or suspected presence of resistance mutations as defined by the International Antiviral Society-United States of America (IAS-USA) resistance guidelines to the individual components of BIK (BIC, FTC, TAF), RPV, and CAB by any historical resistance test result.
  • Any verified Grade 4 laboratory abnormality. A single repeat test is allowed during the Screening phase to verify a result.
  • Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's participation in the study of an compound.
  • Participant has estimated creatine clearance \<30mL/minute per 1.73 meter square (m\^2) via Chronic Kidney Disease-Epidemiology Collaboration () Method.
  • ALT >=3 times (ULN).
  • Exposure to an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to Day 1 of this study.
  • Treatment with any of the following agents within 28 days of Screening:

    • radiation therapy;
    • cytotoxic chemotherapeutic agents;
    • tuberculosis therapy with the exception of isoniazid (isonicotinylhydrazid/INH);
    • anti-coagulation agents;
    • Immunomodulators that alter immune responses such as chronic systemic , interleukins, or interferons.
  • Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.
  • Treatment with any agent, except recognized ART as allowed above, with documented activity against HIV-1 within 28 days of study Day 1. Treatment with acyclovir/valacyclovir is permitted.
  • Use of medications which are associated with Torsade de Pointes.
  • Participants receiving any prohibited medication and who are unwilling or unable to switch to an alternate medication.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
687 participants (actual)

Study arms

  • Active comparator
    Biktarvy (BIK)

    Participants with HIV-1 received BIK tablet orally until month 12. BIK was a fixed dose combination of 50 mg Bictegravir (BIC) + 200 mg Emtricitabine (FTC) + 25 mg Tenofovir alafenamide (TAF).

    Drug: BIKTARVY Tablets (BIK)

  • Experimental
    Oral lead-in phase (OLI)

    Participants with human immunodeficiency viruses (HIV)-1 who chose oral lead in (OLI) received oral 30 milligram (mg) Cabotegravir (CAB) tablet + 25 mg Rilpivirine (RPV) tablet once daily (QD) for one month. At the month 1 visit, the last dose of oral CAB + RPV was given, followed by the first 600 mg CAB long-acting (LA) + 900 mg RPV LA intramuscular injection (IM), and second injection of CAB LA 600 mg + RPV LA 900 mg at month 2, and then subsequent injections once every 2 months (Q2M) until Month 12 (Maintenance Phase). The participants had the option to continue the regimen in the Extension Phase

    Drug: Cabotegravir Tablets · Drug: Rilpivirine Tablets

  • Experimental
    Direct to injections (D2I)

    Participants with HIV-1 who chose direct to injections (D2I) received the first injections of 600 mg CAB LA + 900 mg RPV LA, IM as initial loading doses at Day 1 one month, followed by second and third subsequent injections (CAB LA 600 mg + RPV LA 900 mg) at month 1 and month 3 followed by Q2M until Month 11. The participants had the option to continue the regimen in the Extension Phase.

    Drug: Cabotegravir Injectable Suspension (CAB LA) · Drug: Rilpivirine Injectable Suspension (RPV LA)

  • Active comparator
    Switch Q2M Group

    Eligible participants with HIV-1 who received BIK tablet orally switched treatment after month 12 (Extension Phase) to CAB LA 600 mg + RPV LA 900 mg regimen, administered once every 2 months.

    Drug: Cabotegravir Injectable Suspension (CAB LA) · Drug: Rilpivirine Injectable Suspension (RPV LA)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Plasma Human Immunodeficiency Viruses (HIV)-1 Ribonucleic Acid (RNA) Greater Than or Equal to (>=) 50 Copies Per Milliliter (c/mL) at Month 12/11 - ITT-E Population

    Percentage of participants with plasma HIV 1 RNA \>= 50 c/mL at month 12 was assessed using the food and drug administration (FDA) snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

    Time frame: At month 12/11

  2. Percentage of Participants With Plasma HIV-1 RNA Greater >=50 Copies Per Milliliter (c/mL) at Month 12/11 - mITT-E Population

    Percentage of participants with plasma HIV 1 RNA \>= 50 c/mL at month 12 was assessed using the food and drug administration (FDA) snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

    Time frame: At month 12/11

Secondary outcomes

  1. Percentage of Participants With Plasma HIV-1 RNA Less Than (<)50 c/mL at Month 12/11 - ITT-E Population

    Percentage of participants with plasma HIV 1 RNA \< 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

    Time frame: At month 12/11

  2. Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Month 12/11 -mITT-E Population

    Percentage of participants with plasma HIV 1 RNA \< 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

    Time frame: At month 12/11

  3. Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Month 6/5 - ITT-E Population

    Percentage of participants with plasma HIV 1 RNA \< 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

    Time frame: At month 6/5

  4. Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Month 6/5 - mITT-E Population

    Percentage of participants with plasma HIV 1 RNA \< 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

    Time frame: At month 6/5

  5. Number of Participants With Protocol-defined Confirmed Virologic Failure (CVF) Through Month 6/5 and 12/11

    Protocol-defined confirmed virologic failure was defined as rebound as indicated by two consecutive plasma HIV-1 RNA levels \>= 200 c/mL (Day 1 values are not applicable) after prior suppression to \<200 c/mL. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at Month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. Cumulative number of participants with protocol defined CVF through Month 6/5 and 12/11 has been presented.

    Time frame: Up to month 12

  6. Percentage of Participants With Plasma HIV-1 RNA Greater Than or Equal to (>=) 50 c/mL at Month 6/5

    Percentage of participants with plasma HIV 1 RNA \>= 50 c/mL at month 6 was assessed using the food and drug administration (FDA) snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

    Time frame: At month 6/5

  7. Absolute Values of HIV Viral Load

    Plasma samples were collected for quantitative analysis of HIV-1 RNA. Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: Baseline (Day 1) and up to Month 12

  8. Change From Baseline in HIV Viral Load

    Plasma samples were collected for quantitative analysis of HIV-1 RNA. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value. Logarithm to base 10 values for plasma HIV-1 RNA has been presented. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: Baseline (Day 1) and up to Month 12

  9. Absolute Values of Cluster of Differentiation 4 Plus (CD4+) Cell Count

    Blood samples were collected and CD4+ cell count was assessed using flow cytometry. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: Baseline (Day 1) and up to Month 12

  10. Change From Baseline in CD4+ Cell Count

    Blood samples were collected and CD4+ cell count was assessed using flow cytometry. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: Baseline (Day 1) and up to Month 12

  11. Number of Participants With Treatment-emergent Phenotypic Resistance Through Month 12/11

    Blood samples were collected to evaluate the phenotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of phenotype, fold changes to CAB, RPV, and BIC, replication capacity of Integrase, protease, and reverse transcriptase enzymes at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. No participants in the BIK arm met CVF.

    Time frame: Up to Month 12/11

  12. Number of Participants With Treatment-emergent Phenotypic Resistance Through Month 6/5

    Blood samples were collected to evaluate the phenotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of phenotype, fold changes to CAB, RPV, and BIC, replication capacity of Integrase, protease, and reverse transcriptase enzymes at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. No participants in the BIK arm met CVF.

    Time frame: Up to Month 6/5

  13. Number of Participants With Treatment-emergent Genotypic Resistance Through Month 12/11

    Blood samples were collected to evaluate the genotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of resistance mutations and genotypic susceptibility at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. No participants in the BIK arm met CVF.

    Time frame: Up to Month 12/11

  14. Number of Participants With Treatment-emergent Genotypic Resistance Through Month 6/5

    Blood samples were collected to evaluate the genotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of resistance mutations and genotypic susceptibility at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. No participants in the BIK arm met CVF.

    Time frame: Up to Month 6/5

  15. Change From Baseline in Bone Biomarkers: Specific Alkaline Phosphatase, Procollagen Type 1 N-Terminal Propeptide, Type 1 Collagen Cross-linked C-telopeptide, Osteocalcin (Micrograms Per Liter (ug/L))

    Serum samples were collected to evaluate bone specific biomarkers: specific alkaline phosphatase, procollagen type 1 N-propeptide, type 1 collagen cross-linked C-telopeptide, osteocalcin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: Baseline (Day 1) and up to Month 12

  16. Change From Baseline in Bone Biomarkers: Serum 25-hydroxyvitamin D (Nanomoles Per Liter (Nmol/L))

    Serum samples were collected to evaluate bone specific biomarkers: serum 25-hydroxyvitamin D. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: Baseline (Day 1) and up to Month 12

  17. Change From Baseline in Renal Biomarkers: Specific Serum Beta-2 Microglobulin, Cystatin c, Retinol Binding Protein, Urine Beta-2 Microglobulin (Milligrams Per Liter [mg/L])

    Serum samples were collected to evaluate renal specific biomarkers: specific serum beta-2 microglobulin, cystatin c, retinol binding protein, urine beta-2 microglobulin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: Baseline (Day 1) and up to Month 12

  18. Change From Baseline in Renal Biomarkers: Urine Phosphate (Millimoles Per Liter (mmol/L))

    Serum samples were collected to evaluate renal specific biomarkers: urine phosphate. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: Baseline (Day 1) and up to Month 12

  19. Change From Baseline in Renal Biomarker: Urine Retinol Binding Protein 4 (Microgram Per Liter (ug/L))

    Serum samples were collected to evaluate renal specific biomarkers: urine retinol binding protein 4. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: Baseline (Day 1) and up to Month 12

  20. Change From Baseline in Renal Biomarker: Urine Retinol Binding Protein/Creatinine (Milligram Per Mole (mg/Mol))

    Serum samples were collected to evaluate renal specific biomarkers: urine retinol binding protein/creatinine. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: Baseline (Day 1) and up to Month 12

  21. Change From Baseline in Renal Biomarker: Urine Beta-2 Microglobulin/ Creatinine (Grams Per Mole (g/Mol))

    Serum samples were collected to evaluate renal specific biomarkers: urine beta-2 microglobulin/ creatinine. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: Baseline (Day 1) and up to Month 12

  22. Change From Baseline in Percentage of Participants With Metabolic Syndrome at Month 12/11

    Metabolic syndrome defined as cluster of conditions that occurred together increasing one's risk of heart disease, stroke and type 2 diabetes mellitus (DM). These conditions included increased blood pressure (BP), elevated blood glucose levels, excess body fat around the waist and abnormal fasting cholesterol and triglyceride (TG) levels. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: Baseline (Day 1) and at Month 12/11

  23. Change From Baseline in Percentage of Participants With Metabolic Syndrome at Month 6/5

    Metabolic syndrome defined as cluster of conditions that occurred together increasing one's risk of heart disease, stroke and type 2 diabetes mellitus (DM). These conditions included increased blood pressure (BP), elevated blood glucose levels, excess body fat around the waist and abnormal fasting cholesterol and triglyceride (TG) levels. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit.

    Time frame: Baseline (Day 1) and at month 6/5

  24. Change From Baseline in Homeostasis Model of Assessment-insulin Resistance (HOMA-IR)

    The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance. HOMA-IR is calculated as fasting insulin microunits per liter (microU/L) multiplied by fasting glucose (nmol/L) divided by 22.5. Higher HOMA-IR values indicate increased insulin resistance; values \<2 is generally regarded as normal. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: Baseline (Day 1) and up to Month 12

  25. Percentage of Participants With Treatment Preference as Assessed Using Preference Questionnaire at Month 12/11 - Q2M

    Participants who had switched from the daily oral BIK regimen to CAB + RPV, were assessed as per the preference questionnaire every two months. There were 3 preference questions included to assess the preferred treatment 1) Long-acting injectable HIV medication, 2) Daily oral HIV medication, 3) No Preference. This endpoint was only planned to be analyzed for Q2M arm only. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. Data represented included maintenance withdrawal or Month 12/11.

    Time frame: Up to month 12/11

  26. Change From Baseline in Total Treatment Satisfaction Score Using HIV Treatment Satisfaction Status Questionnaire (HIVTSQs)

    The HIVTSQs total treatment satisfaction score comprised of 11 items based on HIVTSQ questionnaire each graded on a scale of 0 (very dissatisfied) to 6 (very satisfied) which were summed to produce a total score range of 0-66. Higher scores represent greater treatment satisfaction. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: Baseline (Day 1) and up to Month 12

  27. Change From Baseline in Individual Item Scores Using HIVTSQs

    The individual item scores on HIVTSQs scale were rated on a scale of 6 (very satisfied, convenient, flexible, etc.) to -6 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater satisfaction with each aspect of treatment. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: Baseline (Day 1) and up to Month 12

  28. HIV Treatment Satisfaction Change Questionnaire (HIVTSQc) Total Score at Month 12/11

    HIV treatment satisfaction change questionnaire (HIVTSQc) total Score is computed with items 1-11 which were summed to produce a total score range of -33 to 33. Higher score indicated greater improvement in the satisfaction with the treatment and lower score indicated greater deterioration in treatment satisfaction. A score of 0 represents no change. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: At Month 12/11

  29. Individual Item Scores of HIVTSQc at Month 12/11

    Individual item scores were rated on a scale of +3 (much more satisfied', 'much more convenient', 'much more flexible') to -3 (much less satisfied', 'much less convenient', 'much less flexible'). Higher score indicates greater improvement, and lower score indicates greater deterioration in satisfaction with each aspect of treatment. A score of 0 represents no change. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: At Month 12/11

  30. Change From Month 2/1 in Dimension Scores Using Perception of Injection (PIN) Questionnaire - Q2M

    The PIN questionnaire was used to explore the dimension scores based on 4 dimensions including acceptance of injection site reactions (ISRs), Bother from ISRs, Leg movement and Sleep categories. Domain scores were calculated as a mean of all items with the domain. The PIN response options range from 1 (totally acceptable) to 5 (not at all acceptable). This endpoint was only planned to be analyzed for Q2M arm. Month 2/1 refers to the Month 2 (OLI and BIK) visit/Month 1 (DTI) visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: From Month 2/1 up to Month 12

  31. Change From Month 2/1 in Individual Item Scores Using PIN Questionnaire- Q2M

    The PIN questionnaire was used to explore the individual item scores based on anxiety before, pain, satisfaction, anxiety after and willingness categories. The items in the scale are rated on a 5-point scale and questions are phrased in such a way as to ensure that 1 is very dissatisfied and 5 was very satisfied. This endpoint was only planned to be analyzed for Q2M arm. Month 2/1 refers to the Month 2 (OLI and BIK) visit/Month 1 (DTI) visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

    Time frame: From Month 2/1 up to Month 12

07

Results

Posted Sep 13, 2023

Participant flow

The study consists in 2 periods: Maintenance Period and Extension Period. Any participants who successfully completed 12 months of CAB+RPV treatment in the Maintenance Phase had the option to enter the Extension Phase and continued to have access to CAB + RPV.

Maintenance Period (Day 1 - Month 12)
Participant flow — Maintenance Period (Day 1 - Month 12)
MilestoneOral lead-in Phase (OLI)Direct to Injections (D2I)Biktarvy (BIK)Switch Q2M Group
Started1752792270
Completed1522552130
Not completed2324140
Withdrew: Adverse event10310
Withdrew: Lack of efficacy1200
Withdrew: Lost to follow-up3420
Withdrew: Physician decision1010
Withdrew: Withdrawal by subject5890
Withdrew: Protocol deviation2610
Withdrew: Protocol-specified withdrawal criterion met1100
Maintenance + Extension Period
Participant flow — Maintenance + Extension Period
MilestoneOral lead-in Phase (OLI)Direct to Injections (D2I)Biktarvy (BIK)Switch Q2M Group
Started17327400
Completed15024700
Not completed232700
Withdrew: Adverse event10200
Withdrew: Lack of efficacy2200
Withdrew: Lost to follow-up3400
Withdrew: Physician decision1100
Withdrew: Protocol violation2500
Withdrew: Protocol-specified withdrawal criterion met1100
Withdrew: Withdrawal by subject41200
Extension Period (Month 13 - Month 27)
Participant flow — Extension Period (Month 13 - Month 27)
MilestoneOral lead-in Phase (OLI)Direct to Injections (D2I)Biktarvy (BIK)Switch Q2M Group
Started000143
Completed000130
Not completed00013
Withdrew: Adverse event0004
Withdrew: Lack of efficacy0001
Withdrew: Lost to follow-up0001
Withdrew: Physician decision0002
Withdrew: Withdrawal by subject0005

Outcome measures

PrimaryPercentage of Participants With Plasma Human Immunodeficiency Viruses (HIV)-1 Ribonucleic Acid (RNA) Greater Than or Equal to (>=) 50 Copies Per Milliliter (c/mL) at Month 12/11 - ITT-E Population

Percentage of participants with plasma HIV 1 RNA \>= 50 c/mL at month 12 was assessed using the food and drug administration (FDA) snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

Time frame:
At month 12/11
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma Human Immunodeficiency Viruses (HIV)-1 Ribonucleic Acid (RNA) Greater Than or Equal to (>=) 50 Copies Per Milliliter (c/mL) at Month 12/11 - ITT-E Population
Percentage of participantsQ2M (OLI + D2I)Biktarvy (BIK)
Percentage of Participants With Plasma Human Immunodeficiency Viruses (HIV)-1 Ribonucleic Acid (RNA) Greater Than or Equal to (>=) 50 Copies Per Milliliter (c/mL) at Month 12/11 - ITT-E Population1.3 (0.5 to 2.9)0.4 (0.0 to 2.4)
Statistical analysis
  • Q2M (OLI + D2I) vs Biktarvy (BIK) · Difference in percentage: 0.9 · 95% CI -0.5 to 2.2Difference in percentage = percentage of Q2M - percentage of BIK
  • Q2M (OLI + D2I) vs Biktarvy (BIK) · Adjusted difference in percentage: 0.9 · 95% CI -0.5 to 2.2Adjusted difference in percentage = percentage of Q2M - percentage of BIK. Based on cochran-mantel haenszel stratified analysis was adjusted for the baseline stratification factors gender at birth and baseline BMI.
PrimaryPercentage of Participants With Plasma HIV-1 RNA Greater >=50 Copies Per Milliliter (c/mL) at Month 12/11 - mITT-E Population

Percentage of participants with plasma HIV 1 RNA \>= 50 c/mL at month 12 was assessed using the food and drug administration (FDA) snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

Time frame:
At month 12/11
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA Greater >=50 Copies Per Milliliter (c/mL) at Month 12/11 - mITT-E Population
Percentage of participantsQ2M (OLI + D2I)Biktarvy (BIK)
Percentage of Participants With Plasma HIV-1 RNA Greater >=50 Copies Per Milliliter (c/mL) at Month 12/11 - mITT-E Population1.1 (0.4 to 2.6)0.4 (0.0 to 2.5)
Statistical analysis
  • Q2M (OLI + D2I) vs Biktarvy (BIK) · Difference in percentage: 0.7 · 95% CI -0.6 to 2.0Difference in percentage = percentage of Q2M - percentage of BIK
  • Q2M (OLI + D2I) vs Biktarvy (BIK) · Adjusted difference in percentage: 0.7 · 95% CI -0.7 to 2.0Adjusted difference in percentage = percentage of Q2M - percentage of BIK. Based on cochran-mantel haenszel stratified analysis was adjusted for the baseline stratification factors gender at birth and baseline BMI.
SecondaryPercentage of Participants With Plasma HIV-1 RNA Less Than (<)50 c/mL at Month 12/11 - ITT-E Population

Percentage of participants with plasma HIV 1 RNA \< 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

Time frame:
At month 12/11
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA Less Than (<)50 c/mL at Month 12/11 - ITT-E Population
Percentage of participantsQ2M (OLI + D2I)Biktarvy (BIK)
Percentage of Participants With Plasma HIV-1 RNA Less Than (<)50 c/mL at Month 12/11 - ITT-E Population89.4 (86.6 to 92.3)93.0 (89.6 to 96.3)
SecondaryPercentage of Participants With Plasma HIV-1 RNA <50 c/mL at Month 12/11 -mITT-E Population

Percentage of participants with plasma HIV 1 RNA \< 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

Time frame:
At month 12/11
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Month 12/11 -mITT-E Population
Percentage of participantsQ2M (OLI + D2I)Biktarvy (BIK)
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Month 12/11 -mITT-E Population90.2 (87.4 to 92.9)92.8 (89.4 to 96.2)
SecondaryPercentage of Participants With Plasma HIV-1 RNA <50 c/mL at Month 6/5 - ITT-E Population

Percentage of participants with plasma HIV 1 RNA \< 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

Time frame:
At month 6/5
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Month 6/5 - ITT-E Population
Percentage of participantsQ2M (OLI + D2I)Biktarvy (BIK)
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Month 6/5 - ITT-E Population92.7 (90.3 to 95.1)97.8 (95.9 to 99.7)
SecondaryPercentage of Participants With Plasma HIV-1 RNA <50 c/mL at Month 6/5 - mITT-E Population

Percentage of participants with plasma HIV 1 RNA \< 50 c/mL was assessed using the FDA snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

Time frame:
At month 6/5
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Month 6/5 - mITT-E Population
Percentage of participantsQ2M (OLI + D2I)Biktarvy (BIK)
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Month 6/5 - mITT-E Population93.5 (91.2 to 95.8)97.8 (95.8 to 99.7)
SecondaryNumber of Participants With Protocol-defined Confirmed Virologic Failure (CVF) Through Month 6/5 and 12/11

Protocol-defined confirmed virologic failure was defined as rebound as indicated by two consecutive plasma HIV-1 RNA levels \>= 200 c/mL (Day 1 values are not applicable) after prior suppression to \<200 c/mL. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at Month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. Cumulative number of participants with protocol defined CVF through Month 6/5 and 12/11 has been presented.

Time frame:
Up to month 12
Reported as:
Count of participants · Participants
Number of Participants With Protocol-defined Confirmed Virologic Failure (CVF) Through Month 6/5 and 12/11
ParticipantsQ2M (OLI + D2I)Biktarvy (BIK)
Month 6/510
Month 12/1120
SecondaryPercentage of Participants With Plasma HIV-1 RNA Greater Than or Equal to (>=) 50 c/mL at Month 6/5

Percentage of participants with plasma HIV 1 RNA \>= 50 c/mL at month 6 was assessed using the food and drug administration (FDA) snapshot algorithm. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL), along with study drug discontinuation status. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

Time frame:
At month 6/5
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA Greater Than or Equal to (>=) 50 c/mL at Month 6/5
Percentage of participantsQ2M (OLI + D2I)Biktarvy (BIK)
Percentage of Participants With Plasma HIV-1 RNA Greater Than or Equal to (>=) 50 c/mL at Month 6/50.4 (0.1 to 1.6)0 (0.0 to 1.6)
SecondaryAbsolute Values of HIV Viral Load

Plasma samples were collected for quantitative analysis of HIV-1 RNA. Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
Baseline (Day 1) and up to Month 12
Reported as:
Mean · log10 copies per milliliter(c/mL)
Absolute Values of HIV Viral Load
log10 copies per milliliter(c/mL)Q2M (OLI + D2I)Biktarvy (BIK)
Baseline (Day 1)1.5993 ± 0.105591.5947 ± 0.06640
Month 6/51.6002 ± 0.092681.5910 ± 0.01182
Month 12/111.6019 ± 0.130641.5911 ± 0.01552
SecondaryChange From Baseline in HIV Viral Load

Plasma samples were collected for quantitative analysis of HIV-1 RNA. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value. Logarithm to base 10 values for plasma HIV-1 RNA has been presented. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
Baseline (Day 1) and up to Month 12
Reported as:
Mean · log10 c/mL
Change From Baseline in HIV Viral Load
log10 c/mLQ2M (OLI + D2I)Biktarvy (BIK)
Baseline (Day 1)1.5993 ± 0.105591.5947 ± 0.06640
Month 6/50.0015 ± 0.13997-0.0039 ± 0.06826
Month 12/110.0029 ± 0.17038-0.0041 ± 0.07172
SecondaryAbsolute Values of Cluster of Differentiation 4 Plus (CD4+) Cell Count

Blood samples were collected and CD4+ cell count was assessed using flow cytometry. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
Baseline (Day 1) and up to Month 12
Reported as:
Mean · cells per cubic millimeter(cells/mm^3)
Absolute Values of Cluster of Differentiation 4 Plus (CD4+) Cell Count
cells per cubic millimeter(cells/mm^3)Q2M (OLI + D2I)Biktarvy (BIK)
Baseline (Day 1)670.9 ± 282.11679.4 ± 306.89
Month 6/5689.1 ± 284.89673.7 ± 290.46
Month 12/11711.9 ± 297.13717.3 ± 317.82
SecondaryChange From Baseline in CD4+ Cell Count

Blood samples were collected and CD4+ cell count was assessed using flow cytometry. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
Baseline (Day 1) and up to Month 12
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4+ Cell Count
cells/mm^3Q2M (OLI + D2I)Biktarvy (BIK)
Baseline (Day 1)670.9 ± 282.11679.4 ± 306.89
Month 6/520.4 ± 202.38-3.1 ± 197.62
Month 12/1135.2 ± 219.7932.2 ± 208.29
SecondaryNumber of Participants With Treatment-emergent Phenotypic Resistance Through Month 12/11

Blood samples were collected to evaluate the phenotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of phenotype, fold changes to CAB, RPV, and BIC, replication capacity of Integrase, protease, and reverse transcriptase enzymes at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. No participants in the BIK arm met CVF.

Time frame:
Up to Month 12/11
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Phenotypic Resistance Through Month 12/11
ParticipantsQ2M (OLI + D2I)Biktarvy (BIK)
NNRTI20
IN20
SecondaryNumber of Participants With Treatment-emergent Phenotypic Resistance Through Month 6/5

Blood samples were collected to evaluate the phenotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of phenotype, fold changes to CAB, RPV, and BIC, replication capacity of Integrase, protease, and reverse transcriptase enzymes at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. No participants in the BIK arm met CVF.

Time frame:
Up to Month 6/5
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Phenotypic Resistance Through Month 6/5
ParticipantsQ2M (OLI + D2I)Biktarvy (BIK)
NNRTI10
IN10
SecondaryNumber of Participants With Treatment-emergent Genotypic Resistance Through Month 12/11

Blood samples were collected to evaluate the genotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of resistance mutations and genotypic susceptibility at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. No participants in the BIK arm met CVF.

Time frame:
Up to Month 12/11
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Genotypic Resistance Through Month 12/11
ParticipantsQ2M (OLI + D2I)Biktarvy (BIK)
M230L10
Q148R10
K101E10
G118R10
SecondaryNumber of Participants With Treatment-emergent Genotypic Resistance Through Month 6/5

Blood samples were collected to evaluate the genotypic resistance to CAB, RPV, BIC, FTC, and TAF. For each participant, prevalence of resistance mutations and genotypic susceptibility at the time of CVF was assessed. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. No participants in the BIK arm met CVF.

Time frame:
Up to Month 6/5
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Genotypic Resistance Through Month 6/5
ParticipantsQ2M (OLI + D2I)Biktarvy (BIK)
M230L10
Q148R10
SecondaryChange From Baseline in Bone Biomarkers: Specific Alkaline Phosphatase, Procollagen Type 1 N-Terminal Propeptide, Type 1 Collagen Cross-linked C-telopeptide, Osteocalcin (Micrograms Per Liter (ug/L))

Serum samples were collected to evaluate bone specific biomarkers: specific alkaline phosphatase, procollagen type 1 N-propeptide, type 1 collagen cross-linked C-telopeptide, osteocalcin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
Baseline (Day 1) and up to Month 12
Reported as:
Mean · micrograms per liter (ug/L)
Change From Baseline in Bone Biomarkers: Specific Alkaline Phosphatase, Procollagen Type 1 N-Terminal Propeptide, Type 1 Collagen Cross-linked C-telopeptide, Osteocalcin (Micrograms Per Liter (ug/L))
micrograms per liter (ug/L)Q2M (OLI + D2I)Biktarvy (BIK)
Serum Bone Specific Alkaline Phosphatase, Baseline (Day 1)12.7 ± 4.2712.9 ± 4.60
Serum Bone Specific Alkaline Phosphatase, Month 6/50.3 ± 9.890.2 ± 2.60
Serum Bone Specific Alkaline Phosphatase, Month 12/110.1 ± 5.030.5 ± 3.55
Serum Osteocalcin, Baseline (Day 1)21.0 ± 7.3520.4 ± 7.48
Serum Osteocalcin, Month 6/50.4 ± 5.53-0.4 ± 5.11
Serum Osteocalcin, Month 12/110.9 ± 6.11-0.6 ± 5.51
Serum Procollagen 1 N-Terminal Propeptide, Baseline (Day 1)59.1 ± 23.0659.2 ± 23.88
Serum Procollagen 1 N-Terminal Propeptide, Month 6/5-1.5 ± 15.700.1 ± 18.53
Serum Procollagen 1 N-Terminal Propeptide, Month 12/11-0.7 ± 19.730.6 ± 19.63
Serum Type I Collagen C-Telopeptides, Baseline (Day 1)0.4 ± 0.250.5 ± 0.25
Serum Type I Collagen C-Telopeptides, Month 6/5-0.1 ± 0.23-0.1 ± 0.21
Serum Type I Collagen C-Telopeptides, Month 12/110.0 ± 0.250.0 ± 0.22
SecondaryChange From Baseline in Bone Biomarkers: Serum 25-hydroxyvitamin D (Nanomoles Per Liter (Nmol/L))

Serum samples were collected to evaluate bone specific biomarkers: serum 25-hydroxyvitamin D. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
Baseline (Day 1) and up to Month 12
Reported as:
Mean · nanomoles per liter (nmol/L)
Change From Baseline in Bone Biomarkers: Serum 25-hydroxyvitamin D (Nanomoles Per Liter (Nmol/L))
nanomoles per liter (nmol/L)Q2M (OLI + D2I)Biktarvy (BIK)
Baseline (Day 1)61.0 ± 34.6959.9 ± 33.30
Month 6/52.8 ± 29.246.0 ± 34.16
Month 12/11-2.3 ± 29.00-3.1 ± 26.38
SecondaryChange From Baseline in Renal Biomarkers: Specific Serum Beta-2 Microglobulin, Cystatin c, Retinol Binding Protein, Urine Beta-2 Microglobulin (Milligrams Per Liter [mg/L])

Serum samples were collected to evaluate renal specific biomarkers: specific serum beta-2 microglobulin, cystatin c, retinol binding protein, urine beta-2 microglobulin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
Baseline (Day 1) and up to Month 12
Reported as:
Mean · milligrams per liter (mg/L)
Change From Baseline in Renal Biomarkers: Specific Serum Beta-2 Microglobulin, Cystatin c, Retinol Binding Protein, Urine Beta-2 Microglobulin (Milligrams Per Liter [mg/L])
milligrams per liter (mg/L)Q2M (OLI + D2I)Biktarvy (BIK)
Serum beta-2 microglobulin, Baseline (Day 1)1.8 ± 0.401.8 ± 0.38
Serum beta-2 microglobulin, Month 6/50.0 ± 0.280.0 ± 0.28
Serum beta-2 microglobulin, Month 12/110.0 ± 0.330.0 ± 0.32
Serum cystatin C, Baseline (Day 1)0.9 ± 0.130.9 ± 0.14
Serum cystatin C, Month 6/50.0 ± 0.080.0 ± 0.08
Serum cystatin C, Month 12/110.0 ± 0.080.0 ± 0.08
Serum retinol binding protein, Baseline (Day 1)51.3 ± 13.0152.2 ± 12.61
Serum retinol binding protein, Month 6/5-1.0 ± 9.00-0.3 ± 8.75
Serum retinol binding protein, Month 12/11-1.2 ± 9.240.2 ± 9.06
Urine beta-2 microglobulin, Baseline (Day 1)0.2 ± 0.340.2 ± 0.40
Urine beta-2 microglobulin, Month 6/50.0 ± 0.400.1 ± 0.65
Urine beta-2 microglobulin, Month 12/110.0 ± 0.240.1 ± 0.52
SecondaryChange From Baseline in Renal Biomarkers: Urine Phosphate (Millimoles Per Liter (mmol/L))

Serum samples were collected to evaluate renal specific biomarkers: urine phosphate. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
Baseline (Day 1) and up to Month 12
Reported as:
Mean · millimoles per liter (mmol/L)
Change From Baseline in Renal Biomarkers: Urine Phosphate (Millimoles Per Liter (mmol/L))
millimoles per liter (mmol/L)Q2M (OLI + D2I)Biktarvy (BIK)
Baseline (Day 1)20.0 ± 14.0318.4 ± 13.10
Month 6/5-1.0 ± 16.290.4 ± 15.60
Month 12/110.1 ± 16.17-0.6 ± 15.16
SecondaryChange From Baseline in Renal Biomarker: Urine Retinol Binding Protein 4 (Microgram Per Liter (ug/L))

Serum samples were collected to evaluate renal specific biomarkers: urine retinol binding protein 4. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
Baseline (Day 1) and up to Month 12
Reported as:
Mean · microgram per liter (ug/L)
Change From Baseline in Renal Biomarker: Urine Retinol Binding Protein 4 (Microgram Per Liter (ug/L))
microgram per liter (ug/L)Q2M (OLI + D2I)Biktarvy (BIK)
Baseline (Day 1)114.2 ± 111.45100.0 ± 82.00
Month 6/50.8 ± 139.885.7 ± 105.08
Month 12/11-0.6 ± 123.52-1.2 ± 105.26
SecondaryChange From Baseline in Renal Biomarker: Urine Retinol Binding Protein/Creatinine (Milligram Per Mole (mg/Mol))

Serum samples were collected to evaluate renal specific biomarkers: urine retinol binding protein/creatinine. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
Baseline (Day 1) and up to Month 12
Reported as:
Mean · milligram per mole (mg/mol)
Change From Baseline in Renal Biomarker: Urine Retinol Binding Protein/Creatinine (Milligram Per Mole (mg/Mol))
milligram per mole (mg/mol)Q2M (OLI + D2I)Biktarvy (BIK)
Baseline (Day 1)8.6 ± 6.328.0 ± 5.75
Month 6/50.8 ± 6.00-0.8 ± 7.23
Month 12/11-0.5 ± 6.410.0 ± 4.15
SecondaryChange From Baseline in Renal Biomarker: Urine Beta-2 Microglobulin/ Creatinine (Grams Per Mole (g/Mol))

Serum samples were collected to evaluate renal specific biomarkers: urine beta-2 microglobulin/ creatinine. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
Baseline (Day 1) and up to Month 12
Reported as:
Mean · grams per mole (g/mol)
Change From Baseline in Renal Biomarker: Urine Beta-2 Microglobulin/ Creatinine (Grams Per Mole (g/Mol))
grams per mole (g/mol)Q2M (OLI + D2I)Biktarvy (BIK)
Baseline (Day 1)0.0 ± 0.030.0 ± 0.04
Month 6/50.0 ± 0.030.0 ± 0.19
Month 12/110.0 ± 0.020.0 ± 0.04
SecondaryChange From Baseline in Percentage of Participants With Metabolic Syndrome at Month 12/11

Metabolic syndrome defined as cluster of conditions that occurred together increasing one's risk of heart disease, stroke and type 2 diabetes mellitus (DM). These conditions included increased blood pressure (BP), elevated blood glucose levels, excess body fat around the waist and abnormal fasting cholesterol and triglyceride (TG) levels. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
Baseline (Day 1) and at Month 12/11
Reported as:
Number · Percentage of participants
Change From Baseline in Percentage of Participants With Metabolic Syndrome at Month 12/11
Percentage of participantsQ2M (OLI + D2I)Biktarvy (BIK)
Yes (Baseline) to Yes (Month 12/11)99
Yes (Baseline) to No (Month 12/11)57
Yes (Baseline) to Missing (Month 12/11)21
No (Baseline) to Yes (Month 12/11)68
No (Baseline) to No (Month 12/11)6970
No (Baseline) to Missing ((Month 12/11))86
SecondaryChange From Baseline in Percentage of Participants With Metabolic Syndrome at Month 6/5

Metabolic syndrome defined as cluster of conditions that occurred together increasing one's risk of heart disease, stroke and type 2 diabetes mellitus (DM). These conditions included increased blood pressure (BP), elevated blood glucose levels, excess body fat around the waist and abnormal fasting cholesterol and triglyceride (TG) levels. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 visit and Q2M D2I participants at Month 5 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit.

Time frame:
Baseline (Day 1) and at month 6/5
Reported as:
Number · Percentage of participants
Change From Baseline in Percentage of Participants With Metabolic Syndrome at Month 6/5
Percentage of participantsQ2M (OLI + D2I)Biktarvy (BIK)
Yes (Baseline) to Yes (Month 6/5)911
Yes (Baseline) to No (Month 6/5)76
Yes (Baseline) to Missing (Month 6/5)10
No (Baseline) to Yes (Month 6/5)510
No (Baseline) to No (Month 6/5)7471
No (Baseline) to Missing (Month 6/5)52
SecondaryChange From Baseline in Homeostasis Model of Assessment-insulin Resistance (HOMA-IR)

The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance. HOMA-IR is calculated as fasting insulin microunits per liter (microU/L) multiplied by fasting glucose (nmol/L) divided by 22.5. Higher HOMA-IR values indicate increased insulin resistance; values \<2 is generally regarded as normal. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
Baseline (Day 1) and up to Month 12
Reported as:
Mean · HOMA-IR score
Change From Baseline in Homeostasis Model of Assessment-insulin Resistance (HOMA-IR)
HOMA-IR scoreQ2M (OLI + D2I)Biktarvy (BIK)
Baseline (Day 1)2.8 ± 4.053.1 ± 5.06
Month 6/50.3 ± 4.11-0.1 ± 5.09
Month 12/110.2 ± 3.99-0.4 ± 3.76
SecondaryPercentage of Participants With Treatment Preference as Assessed Using Preference Questionnaire at Month 12/11 - Q2M

Participants who had switched from the daily oral BIK regimen to CAB + RPV, were assessed as per the preference questionnaire every two months. There were 3 preference questions included to assess the preferred treatment 1) Long-acting injectable HIV medication, 2) Daily oral HIV medication, 3) No Preference. This endpoint was only planned to be analyzed for Q2M arm only. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit. Data represented included maintenance withdrawal or Month 12/11.

Time frame:
Up to month 12/11
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Preference as Assessed Using Preference Questionnaire at Month 12/11 - Q2M
Percentage of participantsOral lead-in Phase (OLI)Direct to Injections (D2I)
Long-acting injectable HIV medication8792
Daily oral HIV medication74
No Preference65
SecondaryChange From Baseline in Total Treatment Satisfaction Score Using HIV Treatment Satisfaction Status Questionnaire (HIVTSQs)

The HIVTSQs total treatment satisfaction score comprised of 11 items based on HIVTSQ questionnaire each graded on a scale of 0 (very dissatisfied) to 6 (very satisfied) which were summed to produce a total score range of 0-66. Higher scores represent greater treatment satisfaction. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
Baseline (Day 1) and up to Month 12
Reported as:
Mean · Scores on scale
Change From Baseline in Total Treatment Satisfaction Score Using HIV Treatment Satisfaction Status Questionnaire (HIVTSQs)
Scores on scaleQ2M (OLI + D2I)Biktarvy (BIK)
Baseline (Day 1)57.88 ± 7.90658.38 ± 8.229
Month 6/53.99 ± 9.670-0.66 ± 7.417
Month 12/114.21 ± 9.273-1.93 ± 8.045
SecondaryChange From Baseline in Individual Item Scores Using HIVTSQs

The individual item scores on HIVTSQs scale were rated on a scale of 6 (very satisfied, convenient, flexible, etc.) to -6 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater satisfaction with each aspect of treatment. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. For the Q2M arm, data from the Q2M OLI participants at Month 6 and 12 visit and Q2M D2I participants at Month 5 and 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 6 and 12 visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
Baseline (Day 1) and up to Month 12
Reported as:
Mean · Scores on scale
Change From Baseline in Individual Item Scores Using HIVTSQs
Scores on scaleQ2M (OLI + D2I)Biktarvy (BIK)
(Item 1=Satisfaction with current treatment), Baseline (Day 1)5.5 ± 0.865.6 ± 0.75
(Item 1=Satisfaction with current treatment), Month 6/50.1 ± 1.10-0.2 ± 0.91
(Item 1=Satisfaction with current treatment), Month 12/110.2 ± 1.07-0.3 ± 1.00
(Item 2=Controlled HIV), Baseline (Day 1)5.8 ± 0.545.8 ± 0.45
(Item 2=Controlled HIV), Month 6/50.0 ± 0.80-0.1 ± 0.55
(Item 2=Controlled HIV), Month 12/110.0 ± 0.70-0.1 ± 0.69
(Item 3=Satisfaction with side effects of present treatment), Baseline (Day 1)5.5 ± 0.915.5 ± 1.02
(Item 3=Satisfaction with side effects of present treatment), Month 6/5-0.3 ± 1.420.0 ± 1.21
(Item 3=Satisfaction with side effects of present treatment), Month 12/11-0.1 ± 1.380.0 ± 1.16
(Item 4=Satisfaction with current treatment demands), Baseline (Day 1)5.2 ± 1.165.2 ± 1.21
(Item 4=Satisfaction with current treatment demands), Month 6/50.4 ± 1.32-0.1 ± 1.28
(Item 4=Satisfaction with current treatment demands), Month 12/110.3 ± 1.33-0.2 ± 1.35
(Item 5=Treatment convenience), Baseline (Day 1)5.0 ± 1.245.2 ± 1.16
(Item 5=Treatment convenience), Month 6/50.6 ± 1.42-0.1 ± 1.30
(Item 5=Treatment convenience), Month 12/110.7 ± 1.43-0.2 ± 1.33
(Item 6=Treatment flexibility), Baseline (Day 1)4.7 ± 1.704.9 ± 1.55
(Item 6=Treatment flexibility), Month 6/50.9 ± 1.770.0 ± 1.58
(Item 6=Treatment flexibility), Month 12/110.9 ± 1.74-0.1 ± 1.58
(Item 7=Satisfaction with understanding of HIV), Baseline (Day 1)5.5 ± 0.805.5 ± 0.92
(Item 7=Satisfaction with understanding of HIV), Month 6/50.2 ± 0.810.1 ± 0.75
(Item 7=Satisfaction with understanding of HIV), Month 12/110.1 ± 0.860.1 ± 0.78
(Item 8=Treatment fitting in with lifestyle), Baseline (Day 1)5.0 ± 1.205.1 ± 1.11
(Item 8=Treatment fitting in with lifestyle), Month 6/50.7 ± 1.36-0.1 ± 1.26
(Item 8=Treatment fitting in with lifestyle), Month 12/110.7 ± 1.31-0.2 ± 1.38
(Item 9=Recommendation of current treatment for HIV), Baseline (Day 1)5.5 ± 0.865.5 ± 1.02
(Item 9=Recommendation of current treatment for HIV), Month 6/50.2 ± 1.100.0 ± 1.09
(Item 9=Recommendation of current treatment for HIV), Month 12/110.2 ± 1.04-0.1 ± 1.04
(Item 10=Satisfaction with present treatment continuation), Baseline (Day 1)4.9 ± 1.234.9 ± 1.28
(Item 10=Satisfaction with present treatment continuation), Month 6/50.8 ± 1.540.0 ± 1.38
(Item 10=Satisfaction with present treatment continuation), Month 12/110.9 ± 1.49-0.2 ± 1.45
(Item 11=Ease or difficulty with current treatment), Baseline (Day 1)5.2 ± 1.105.3 ± 1.06
(Item 11=Ease or difficulty with current treatment), Month 6/50.5 ± 1.34-0.2 ± 1.20
(Item 11=Ease or difficulty with current treatment), Month 12/110.5 ± 1.34-0.3 ± 1.13
(Item 12=Satisfaction with amount of discomfort/pain with current treatment), Baseline (Day 1)5.5 ± 1.025.6 ± 0.94
(Item 12=Satisfaction with amount of discomfort/pain with current treatment), Month 6/5-0.6 ± 1.64-0.1 ± 0.93
(Item 12=Satisfaction with amount of discomfort/pain with current treatment), Month 12/11-0.5 ± 1.54-0.2 ± 1.09
SecondaryHIV Treatment Satisfaction Change Questionnaire (HIVTSQc) Total Score at Month 12/11

HIV treatment satisfaction change questionnaire (HIVTSQc) total Score is computed with items 1-11 which were summed to produce a total score range of -33 to 33. Higher score indicated greater improvement in the satisfaction with the treatment and lower score indicated greater deterioration in treatment satisfaction. A score of 0 represents no change. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
At Month 12/11
Reported as:
Mean · Scores on scale
HIV Treatment Satisfaction Change Questionnaire (HIVTSQc) Total Score at Month 12/11
Scores on scaleQ2M (OLI + D2I)Biktarvy (BIK)
HIV Treatment Satisfaction Change Questionnaire (HIVTSQc) Total Score at Month 12/1126.97 ± 10.13516.89 ± 14.299
SecondaryIndividual Item Scores of HIVTSQc at Month 12/11

Individual item scores were rated on a scale of +3 (much more satisfied', 'much more convenient', 'much more flexible') to -3 (much less satisfied', 'much less convenient', 'much less flexible'). Higher score indicates greater improvement, and lower score indicates greater deterioration in satisfaction with each aspect of treatment. A score of 0 represents no change. For the Q2M arm, data from the Q2M OLI participants at Month 12 visit and Q2M D2I participants at Month 11 visit were combined as the study objective was to demonstrate the non-inferior antiviral activity of (Q2M) (OLI+ D2I combined) compared to BIK. For BIK arm, data was collected at month 12 visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
At Month 12/11
Reported as:
Mean · Scores on scale
Individual Item Scores of HIVTSQc at Month 12/11
Scores on scaleQ2M (OLI + D2I)Biktarvy (BIK)
Item 1=Satisfaction with current treatment2.56 ± 1.0431.60 ± 1.417
Item 2=Controlled HIV2.47 ± 1.0861.88 ± 1.375
Item 3=Satisfaction with side effects of present treatment2.10 ± 1.3881.63 ± 1.463
Item 4=Satisfaction with current treatment demands2.41 ± 1.1091.42 ± 1.560
Item 5=Treatment convenience2.50 ± 1.0701.38 ± 1.520
Item 6=Treatment flexibility2.41 ± 1.1381.24 ± 1.591
Item 7=Satisfaction with understanding of HIV2.35 ± 1.0651.94 ± 1.297
Item 8=Treatment fitting in with lifestyle2.56 ± 0.9941.43 ± 1.489
Item 9=Recommendation of current treatment for HIV2.61 ± 1.0651.73 ± 1.467
Item 10=Satisfaction with present treatment continuation2.58 ± 1.0931.22 ± 1.602
Item 11=Ease or difficulty with current treatment2.46 ± 1.1071.43 ± 1.542
Item 12=Satisfaction with amount of discomfort/pain with current treatment1.85 ± 1.5301.64 ± 1.465
SecondaryChange From Month 2/1 in Dimension Scores Using Perception of Injection (PIN) Questionnaire - Q2M

The PIN questionnaire was used to explore the dimension scores based on 4 dimensions including acceptance of injection site reactions (ISRs), Bother from ISRs, Leg movement and Sleep categories. Domain scores were calculated as a mean of all items with the domain. The PIN response options range from 1 (totally acceptable) to 5 (not at all acceptable). This endpoint was only planned to be analyzed for Q2M arm. Month 2/1 refers to the Month 2 (OLI and BIK) visit/Month 1 (DTI) visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
From Month 2/1 up to Month 12
Reported as:
Mean · Scores on scale
Change From Month 2/1 in Dimension Scores Using Perception of Injection (PIN) Questionnaire - Q2M
Scores on scaleOral lead-in Phase (OLI)Direct to Injections (D2I)
Bother of ISRs, Month 2/11.58 ± 0.5681.60 ± 0.583
Bother of ISRs, Month 6/50.01 ± 0.528-0.03 ± 0.590
Bother of ISRs, Month 12/110.08 ± 0.594-0.04 ± 0.583
Leg Movement, Month 2/11.93 ± 1.0131.83 ± 0.913
Leg Movement, Month 6/5-0.14 ± 0.779-0.22 ± 0.868
Leg Movement, Month 12/11-0.18 ± 0.859-0.24 ± 0.817
Sleep, Month 2/11.83 ± 0.9361.87 ± 0.965
Sleep, Month 6/5-0.01 ± 0.915-0.16 ± 0.869
Sleep, Month 12/11-0.07 ± 0.948-0.17 ± 0.870
Acceptance, Month 2/12.02 ± 1.0172.05 ± 0.949
Acceptance, Month 6/5-0.14 ± 0.906-0.13 ± 0.879
Acceptance, Month 12/11-0.20 ± 0.873-0.26 ± 0.856
SecondaryChange From Month 2/1 in Individual Item Scores Using PIN Questionnaire- Q2M

The PIN questionnaire was used to explore the individual item scores based on anxiety before, pain, satisfaction, anxiety after and willingness categories. The items in the scale are rated on a 5-point scale and questions are phrased in such a way as to ensure that 1 is very dissatisfied and 5 was very satisfied. This endpoint was only planned to be analyzed for Q2M arm. Month 2/1 refers to the Month 2 (OLI and BIK) visit/Month 1 (DTI) visit. Month 6/5 refers to the Month 6 (OLI and BIK) visit/Month 5 (DTI) visit. Month 12/11 refers to the Month 12 (OLI and BIK) visit/Month 11 (DTI) visit.

Time frame:
From Month 2/1 up to Month 12
Reported as:
Mean · Scores on scale
Change From Month 2/1 in Individual Item Scores Using PIN Questionnaire- Q2M
Scores on scaleOral lead-in Phase (OLI)Direct to Injections (D2I)
Anxiety Before, Month 2/11.9 ± 1.021.9 ± 1.02
Anxiety Before, Month 6/5-0.14 ± 1.021-0.22 ± 1.000
Anxiety Before, Month 12/11-0.28 ± 0.973-0.22 ± 0.914
Pain, Month 2/11.8 ± 0.882.0 ± 0.93
Pain, Month 6/50.09 ± 0.907-0.03 ± 0.935
Pain, Month 12/110.13 ± 0.9950.02 ± 0.943
Satisfaction, Month 2/11.7 ± 0.901.6 ± 0.81
Satisfaction, Month 6/5-0.06 ± 0.8370.00 ± 0.867
Satisfaction, Month 12/11-0.12 ± 0.861-0.11 ± 0.830
Anxiety After, Month 2/11.8 ± 1.121.7 ± 0.96
Anxiety After, Month 6/5-0.14 ± 0.994-0.04 ± 0.916
Anxiety After, Month 12/11-0.24 ± 0.947-0.16 ± 0.850
Willingness, Month 2/11.4 ± 0.761.4 ± 0.78
Willingness, Month 6/50.01 ± 0.716-0.08 ± 0.794
Willingness, Month 12/11-0.01 ± 0.744-0.10 ± 0.742

Adverse events

Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to end of Extension Phase (approximately Month 27).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral lead-in Phase (OLI)0/175 (0%)11/175 (6.3%)156/175 (89.1%)
Direct to Injections (D2I)0/279 (0%)10/279 (3.6%)257/279 (92.1%)
Biktarvy (BIK)1/227 (0.4%)15/227 (6.6%)77/227 (33.9%)
Switch Q2M Group1/145 (0.7%)5/145 (3.4%)76/145 (52.4%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventOral lead-in Phase (OLI)Direct to Injections (D2I)Biktarvy (BIK)Switch Q2M Group
Alanine aminotransferase increasedInvestigations2/1751/2790/2270/145
Road traffic accidentInjury, poisoning and procedural complications0/1751/2792/2270/145
AppendicitisInfections and infestations0/1750/2791/2271/145
PyelonephritisInfections and infestations0/1751/2790/2271/145
Cytomegalovirus infectionInfections and infestations0/1750/2790/2271/145
Hepatitis CInfections and infestations0/1750/2790/2271/145
Sudden deathGeneral disorders0/1750/2790/2271/145
Hepatitis acuteHepatobiliary disorders0/1750/2790/2271/145
Herpes simplex meningitisInfections and infestations1/1750/2790/2270/145
Herpes simplex meningoencephalitisInfections and infestations1/1750/2790/2270/145
Most frequent other events
Showing 10 of 14
Most frequent other events
EventOral lead-in Phase (OLI)Direct to Injections (D2I)Biktarvy (BIK)Switch Q2M Group
Injection site painGeneral disorders106/175182/2791/22755/145
COVID-19Infections and infestations34/17550/27938/22721/145
HeadacheNervous system disorders17/17535/27912/2270/145
Injection site indurationGeneral disorders20/17517/2790/2270/145
Injection site noduleGeneral disorders17/17526/2790/2270/145
Injection site discomfortGeneral disorders17/17526/2790/2270/145
FatigueGeneral disorders17/17514/2796/2270/145
Injection site swellingGeneral disorders15/17527/2790/2270/145
PyrexiaGeneral disorders10/17526/2798/2270/145
NasopharyngitisInfections and infestations8/17525/27910/2270/145

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Oral lead-in Phase (OLI)Direct to Injections (D2I)Biktarvy (BIK)Total
Mean38.5 ± 11.3839.0 ± 11.0938.6 ± 11.4138.7 ± 11.26
Sex: Female, Male
Sex: Female, Male(Participants)Oral lead-in Phase (OLI)Direct to Injections (D2I)Biktarvy (BIK)Total
Female275241120
Male148227186561
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Oral lead-in Phase (OLI)Direct to Injections (D2I)Biktarvy (BIK)Total
American Indian or Alaska Native104216
Asian - Central/South Asian Heritage0303
Asian - East Asian Heritage1023
Asian - Japanese Heritage410620
Asian - South East Asian Heritage2338
Black or African American405649145
Native Hawaiian or Other Pacific Islander0011
White - Arabic/North African Heritage1051025
White - White/Caucasian/European Heritage104194149447
Mixed White Race0011
Multiple44412
08

Study locations

117 sites
  • GSK Investigational Site
    Bakersfield, California 93301, United States
  • GSK Investigational Site
    Beverly Hills, California 90211, United States
  • GSK Investigational Site
    Los Angeles, California 90027, United States
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    Los Angeles, California 90036, United States
  • GSK Investigational Site
    Palm Springs, California 92262, United States
  • GSK Investigational Site
    San Francisco, California 94102, United States
  • GSK Investigational Site
    Denver, Colorado 80204, United States
  • GSK Investigational Site
    New Haven, Connecticut 06510, United States
  • GSK Investigational Site
    Fort Pierce, Florida 34982, United States
  • GSK Investigational Site
    Miami, Florida 33133, United States
  • GSK Investigational Site
    Pensacola, Florida 32503, United States
  • GSK Investigational Site
    Tampa, Florida 33602, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33407, United States
  • GSK Investigational Site
    Atlanta, Georgia 30033, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Chicago, Illinois 60613, United States
  • GSK Investigational Site
    Kansas City, Kansas 66160, United States
  • GSK Investigational Site
    Wichita, Kansas 67214, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70112, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70117, United States
  • GSK Investigational Site
    Baltimore, Maryland 21201, United States
  • GSK Investigational Site
    Boston, Massachusetts 02043, United States
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
  • GSK Investigational Site
    Southfield, Michigan 48075, United States
  • GSK Investigational Site
    Newark, New Jersey 07103, United States
  • GSK Investigational Site
    Bronx, New York 10467, United States
  • GSK Investigational Site
    Syracuse, New York 13210, United States
  • GSK Investigational Site
    Durham, North Carolina 27710, United States
  • GSK Investigational Site
    Greensboro, North Carolina 27401-1209, United States
  • GSK Investigational Site
    Greenville, North Carolina 27834, United States
  • GSK Investigational Site
    Huntersville, North Carolina 28078, United States
  • GSK Investigational Site
    Wilmington, North Carolina 28401, United States
  • GSK Investigational Site
    Toledo, Ohio 43614, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • GSK Investigational Site
    Bellaire, Texas 77401, United States
  • GSK Investigational Site
    Dallas, Texas 75208, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Houston, Texas 77098, United States
  • GSK Investigational Site
    Seattle, Washington 98104, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53226, United States
  • GSK Investigational Site
    Darlinghurst, Sydney, New South Wales 2010, Australia
  • GSK Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • GSK Investigational Site
    Sydney, New South Wales 2010, Australia
  • GSK Investigational Site
    Prahran, Victoria 3181, Australia
  • GSK Investigational Site
    Innsbruck, A-6020, Austria
  • GSK Investigational Site
    Linz, 4021, Austria
  • GSK Investigational Site
    Wien, A-1090, Austria
  • GSK Investigational Site
    Hasselt, 3500, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Liege, 4000, Belgium
  • GSK Investigational Site
    Lodelinsart, 6042, Belgium
  • GSK Investigational Site
    Winnipeg, Manitoba R3A 1R9, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5B 1W8, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1K2, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2N2, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4E9, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4P9, Canada
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
  • GSK Investigational Site
    Montréal, Quebec H3A 1T1, Canada
  • GSK Investigational Site
    Regina, Saskatchewan S4P 0W5, Canada
  • GSK Investigational Site
    Bobigny, 93009, France
  • GSK Investigational Site
    Bordeaux Cedex, 33076, France
  • GSK Investigational Site
    Clermont-Ferrand, 63000, France
  • GSK Investigational Site
    Créteil, 94010, France
  • GSK Investigational Site
    Le Kremlin-Bicetre Cedex, 94275, France
  • GSK Investigational Site
    Nantes, 44093, France
  • GSK Investigational Site
    Nice cedex 3, 06202, France
  • GSK Investigational Site
    Tourcoing cedex, 59208, France
  • GSK Investigational Site
    Muenchen, Bayern 80336, Germany
  • GSK Investigational Site
    Aachen, Nordrhein-Westfalen 52062, Germany
  • GSK Investigational Site
    Bochum, Nordrhein-Westfalen 44787, Germany
  • GSK Investigational Site
    Bonn, Nordrhein-Westfalen 53127, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 50668, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 50674, Germany
  • GSK Investigational Site
    Berlin, 10117, Germany
  • GSK Investigational Site
    Berlin, 10439, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    Dublin, 8, Ireland
  • GSK Investigational Site
    Dublin, D09 V2N0, Ireland
  • GSK Investigational Site
    Modena, Emilia-Romagna 41124, Italy
  • GSK Investigational Site
    Roma, Lazio 00149, Italy
  • GSK Investigational Site
    Bergamo, Lombardia 24127, Italy
  • GSK Investigational Site
    Brescia, Lombardia 25123, Italy
  • GSK Investigational Site
    Busto Arsizio (VA), Lombardia 21052, Italy
  • GSK Investigational Site
    Milano, Lombardia 20127, Italy
  • GSK Investigational Site
    Milano, Lombardia 20157, Italy
  • GSK Investigational Site
    Pavia, Lombardia 27100, Italy
  • GSK Investigational Site
    Torino, Piemonte 10149, Italy
  • GSK Investigational Site
    Aichi, 460-0001, Japan
  • GSK Investigational Site
    Osaka, 540-0006, Japan
  • GSK Investigational Site
    Tokyo, 108-8639, Japan
  • GSK Investigational Site
    Tokyo, 162-8655, Japan
  • GSK Investigational Site
    Amsterdam, 1091 HA, Netherlands
  • GSK Investigational Site
    Amsterdam, 1105 AZ, Netherlands
  • GSK Investigational Site
    Alcala de Henares, 28805, Spain
  • GSK Investigational Site
    Burgos, 09006, Spain
  • GSK Investigational Site
    Huelva, 21005, Spain

Showing the first 100 of 117 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Karver TS, Pascual-Bernaldez M, Berni A, Hnoosh A, Castagna A, Messiaen P, Puerto MJG, Bloch M, Adachi E, Sinclair G, Felizarta F, Angel JB, Sutton K, Sutherland-Phillips D, D'Amico R, Kerrigan D. Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial. AIDS Patient Care STDS. 2023 Jan;37(1):53-59. doi: 10.1089/apc.2022.0168. PubMed 36626155 ↗
  • Ramgopal MN, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S, Osiyemi O, Walmsley S, Sims J, Di Perri G, Sutton K, Sutherland-Phillips D, Berni A, Latham CL, Zhang F, D'Amico R, Pascual Bernaldez M, Van Solingen-Ristea R, Van Eygen V, Patel P, Chounta V, Spreen WR, Garges HP, Smith K, van Wyk J. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023 Sep;10(9):e566-e577. doi: 10.1016/S2352-3018(23)00136-4. Epub 2023 Aug 8. PubMed 37567205 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · viivhealthcare.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jul 2022, 20 months.

Results were first posted in Sep 2023, 1 year 2 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 20 months is close to that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2020
First posted
Sep 9, 2020
StartActual
Nov 9, 2020
Primary completionActual
Jul 13, 2022
CompletionActual
Apr 17, 2023
Results first posted
Sep 13, 2023
Last update
Jun 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04542070
Lead sponsor
ViiV Healthcare
Collaborators
Janssen, LP
Responsible party
Sponsor
First posted
Sep 9, 2020
Start date
Nov 9, 2020
Primary completion
Jul 13, 2022
Completion
Apr 17, 2023
Results posted
Sep 13, 2023
Last update
Jun 4, 2024

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabotegravir · Rilpivirine

Start the discussion